Vtvtherapeutics
NASDAQ: VTVTHigh Point, US · Delaware corporation · 60 employees on LinkedIn · 2 known investors
vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases. Its lead candidate, cadisegliatin, is a glucokinase activator in Phase 3 trials for treating type 1 diabetes.
Founders & leadership
RH
Rudy HowardExecutive
SH
Stephen HolcombeExecutive
LA
Larry AltstielExecutive
JK
Jeffrey KindlerExecutive
PM
Paul MeisterNamed on SEC filing
PS
Paul SavasNamed on SEC filing
NS
Noel SpiegelNamed on SEC filing
HW
Howard WeinerNamed on SEC filing
JF
John FryNamed on SEC filing
SC
Steven CohenNamed on SEC filing
CP
Craig ParkerNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$70.5M disclosed across 6 of 7 rounds · 2017–2024
▶$51MraisedMar 2024 · 4 investors · PharmaceuticalsRule 506(b)
▶$51MraisedMar 2024 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Keith HarrisDirector
- Steven TuchExecutive Officer
- Srinivas AkkarajuDirector
- Raymond CheongDirector
- Richard NelsonExecutive Officer, Director
- Paul J. SekhriExecutive Officer, Director
- John A. FryDirector
- Fahed Al MarzooqiDirector
- Howard L. WeinerDirector
- Offering amount
- $51M
- Amount sold
- $51M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedJan 2020 · PharmaceuticalsRule 506(b)
▶$2MraisedJan 2020 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rudy HowardExecutive Officer
- Noel SpiegelDirector
- Paul SavasDirector
- John FryDirector
- Stephen HolcombeExecutive Officer
- Howard WeinerDirector
- Jeffrey KindlerDirector
- Hersh KozlovDirector
- Offering amount
- $10M
- Amount sold
- $2M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2MraisedOct 2019 · PharmaceuticalsRule 506(b)
▶$2MraisedOct 2019 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Howard WeinerDirector
- Paul SavasDirector
- John FryDirector
- Hersh KozlovDirector
- Jeffrey KindlerExecutive Officer, Director
- Rudy HowardExecutive Officer
- Stephen HolcombeExecutive Officer
- Noel SpiegelDirector
- Offering amount
- $10M
- Amount sold
- $2M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$4MraisedJul 2019 · PharmaceuticalsRule 506(b)
▶$4MraisedJul 2019 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey KindlerExecutive Officer, Director
- Steven CohenDirector
- John FryDirector
- Paul SavasDirector
- Howard WeinerDirector
- Noel SpiegelDirector
- Rudy HowardExecutive Officer
- Stephen HolcombeExecutive Officer
- Offering amount
- $9M
- Amount sold
- $4M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.5MraisedJan 2019 · PharmaceuticalsRule 506(b)
▶$1.5MraisedJan 2019 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rudy HowardExecutive Officer
- Howard WeinerDirector
- Paul SavasDirector
- Noel SpiegelDirector
- Steven CohenDirector
- Stephen HolcombeExecutive Officer
- John FryDirector
- Craig ParkerDirector
- Jeffrey KindlerExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $1.5M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$10MofferedAug 2018 · PharmaceuticalsRule 506(b)
▶$10MofferedAug 2018 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Craig ParkerDirector
- Howard WeinerDirector
- Paul MeisterDirector
- Stephen HolcombeExecutive Officer
- Noel SpiegelDirector
- Paul SavasDirector
- Rudy HowardExecutive Officer
- Steven CohenDirector
- Jeffrey KindlerExecutive Officer, Director
- John FryDirector
- Offering amount
- $10M
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$10MraisedDec 2017 · 1 investors · PharmaceuticalsRule 506(b)
▶$10MraisedDec 2017 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rudy HowardExecutive Officer
- Paul MeisterDirector
- Stephen HolcombeExecutive Officer
- Paul SavasDirector
- Noel SpiegelDirector
- Howard WeinerDirector
- John FryDirector
- Larry AltstielExecutive Officer
- Steven CohenDirector
- Craig ParkerDirector
- Jeffrey KindlerExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Robinhood9 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView9 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Public8 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Seeking Alpha8 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwits8 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
TipRanks7 shared keywordsFinancial analysis and stock research platform.
Companies competing with Vtvtherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Vtvtherapeutics do?
- vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases. Its lead candidate, cadisegliatin, is a glucokinase activator in Phase 3 trials for treating type 1 diabetes.
- Who are Vtvtherapeutics's investors?
- Vtvtherapeutics's investors include JDRF T1D Fund, Samsara BioCapital.
- How much funding has Vtvtherapeutics raised?
- Vtvtherapeutics has disclosed $70.5M raised across 6 of its 7 known rounds.
- Where is Vtvtherapeutics headquartered?
- Vtvtherapeutics is headquartered in High Point, US.